Biosynthesis breakthrough could lead to a more cost-effective, sustainable supply of active ingredient for actinic keratosis

Actinic ("solar") keratosis lesions can develop into skin cancer

6 September 2016 – Evolva (SIX: EVE) announces the publication of an important study in the Proceedings of the National Academies of Science (PNAS) that describes the latest breakthrough for the biosynthetic production of prescription medicines.

The PNAS paper describes the discovery of the initial enzymatic steps towards biosynthesis of ingenol mebutate, a prescription topical agent used for the treatment of actinic keratosis lesions on the skin, as well as for other bioactive macrocyclic diterpenoids.

Actinic keratosis, sometimes referred to as “solar keratosis”, appears on the skin as a rough, scaly, off-color lesion (or patchwork of lesions). They typically develop on the scalp, face, lips, ears, hands, arms, and neck following years of exposure to the sun. Actinic keratosis lesions tend to grow very slowly. As such, they are more commonly observed on the skin of older adults. Some of these lesions become cancerous.

Currently, ingenol mebutate is derived from expensive and inefficient plant extraction and chemical synthesis production routes. Looking ahead, this same ingredient can now be produced using a more cost-effective and sustainable biosynthesis production route.

Evolva research scientist Harald Heider and Evolva scientific advisor and University of Copenhagen Plant Biochemistry Professor Birger Lindberg Møller are among the principal investigators and co-authors on this PNAS paper. Click here to access the study, Oxidation and cyclization of casbene in the biosynthesis of Euphorbia factors from mature seeds of Euphorbia lathyris L.



Download press release in English

About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, resveratrol, vanillin, nootkatone and saffron. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see Questions about our fermentation approach? Have a look at our video.
Contact Details

Neil Goldsmith
+ 41 61 485 2005
Jakob Dynnes Hansen
+ 41 61 485 2034
Paul Verbraeken
+ 41 61 485 2035

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.